Madison start-up company BioSentinel Inc. has been recognized for its industry leading research and will have six presentations at the 47th Annual Interagency Botulism Research Coordinating Committee meeting in Atlanta, Ga., Nov. 1-5.
Presentations and posters on BioSentinel’s latest assay technologies will include information on upcoming product releases: an botulinum neurotoxin (BoNT) activity assay that is compatible with complex matrices; and BoCell™ A, a cell-based assay for the detection of BoNT. These assays will be the first products on the market that allow for rapid detection of the deadly toxin’s activity in food products, environmental samples, and in pharmaceutical products. In addition, the BoCell™ A assay will reduce the use of animal testing, the current standard for BoNT detection.
Among the presentations and poster sessions:
— Ward Tucker, Ph.D., director of research and development, will give an oral presentation titled, “Methods for the detection of botulinum neurotoxin activity.”
— Dhammika Atapattu, M.D., Ph.D., will have a poster presentation titled, “Development and optimization of a cell-based assay for the detection of botulinum neurotoxin serotype A.”
— Mark Dunning, Ph.D., will have a poster presentation titled, “Detection of botulinum neurotoxin serotype A proteolytic activity in complex matrices.”
–Timothy Piazza, Ph.D., will have a poster presentation titled, “Development of In Vitro Assays for the Detection of Avian Botulism Type E in the Great Lakes.”
— Daniel Ruge, M.S., will have a poster presentation titled, “Validation of the BoTest™ Assay for determination of endopeptidase activity in formulated botulinum neurotoxin serotype A.”Ruge also will have a poster presentation titled, “Comparability of BoTest™ Assay with an LD50 Potency Assay.”
— Michael Cannon, senior managing partner of BioSentinel, said the company is achieving goals it set for itself.
“We are providing accurate and rapid tests for botulinum neurotoxin to industry and government agencies as well as establishing a network with government laboratories engaged in botulinum research,” Cannon said. “The invitation from the interagency botulism committee is welcome recognition of our hard work.’’
BioSentinel, Inc. is a startup biotech company founded to develop tools for the detection of botulinum neurotoxins and uses of those tools for biodefense purposes. Founded in partnership with Wisconsin Alumni Research Foundation, BioSentinel began operations in June 2007. BioSentinel has ongoing collaborations with U.S. Army Medical Research Institute of Infectious Diseases, U.S. Army Medical Institute of Chemical Defense, National Wildlife Health Center, UW-Madison, the Wisconsin Security Research Consortium and private laboratories aimed at furthering botulinum neurotoxin research and reducing the threat of botulinum neurotoxins as bioterrorism weapons.
More information about BoTest™ and how it can be ordered can be found online at www.biosentinelpharma.com.
Distributed through Wisconsin Technology Council News Services / www.wisconsintechnologycouncil.com
Web site: http://www.biosentinelpharma.com